Serious adverse events · High‐risk HIV‐uninfected individuals (including serodiscordant couples, men who have sex with men and sex workers)
TDF+ FTC showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
HIV infection · High‐risk individuals (including serodiscordant couples, men who have sex with men and sex workers)
TDF probably leads to lower HIV infection compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · High‐risk individuals (including serodiscordant couples, men who have sex with men and sex workers)
TDF showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with initial treatment of HIV infection in antiretroviral‐naive individuals
It is very uncertain whether d4T changes mortality compared with AZT (very low certainty).
1 finding from 1 review
Clinical progression · patients with initial treatment of HIV infection in antiretroviral‐naive individuals
d4T showed no clear difference in clinical progression compared with AZT (low certainty).
1 finding from 1 review
Severe adverse events · patients with initial treatment of HIV infection in antiretroviral‐naive individuals
d4T showed no clear difference in severe adverse events compared with AZT (low certainty).
1 finding from 1 review
Virologic response · patients with initial treatment of HIV infection in antiretroviral‐naive individuals
d4T showed no clear difference in virologic response compared with AZT (low certainty).
1 finding from 1 review
Adherence/tolerability/retention · patients with initial treatment of HIV infection in antiretroviral‐naive individuals
d4T showed no clear difference in adherence/tolerability/retention compared with AZT (low certainty).
1 finding from 1 review
Immunologic response · patients with initial treatment of HIV infection in antiretroviral‐naive individuals
1 finding from 1 review
Drug resistance · patients with initial treatment of HIV infection in antiretroviral‐naive individuals
It is very uncertain whether d4T changes drug resistance compared with AZT (very low certainty).
1 finding from 1 review
Quit at longest · individuals who smoke cigarettes and are admitted to a hospital for medical or surgical care
It is very uncertain whether smoking cessation counselling changes quit at longest compared with no smoking cessation counselling, grouped by intensity of intervention (very low certainty).
4 findings from 1 review
RR 1.52 [0.8, 2.89]
2 studies · 1417 participants
Very low
RR 1.27 [1.02, 1.58]
12 studies · 4432 participants
Moderate
RR 1.04 [0.9, 1.2]
7 studies · 4627 participants
Very low
Show 1 more finding
Intervention not reported
Total studies: 47 Total participants: 4398 · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
47 participants
GRADE not reported
Intervention not reported
TXA given intra‐articularly at a total dose of 2 g intraoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
2 participants
Low
Intervention not reported
TXA given intravenously at a total dose of 1 g intraoperatively and postoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
1 participants
Low
Intervention not reported
TXA given orally at a total dose of greater than 3 g pre‐incision and postoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
3 participants
Very low
Intervention not reported
TXA given orally at a total dose of 2 g pre‐incision · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
2 participants
Low
Intervention not reported
TXA given intra‐articularly at a total dose of 1 g intraoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
1 participants
Low
Intervention not reported
TXA given intravenously at a total dose of greater than 3 g intraoperatively and postoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
3 participants
Moderate
Intervention not reported
TXA given intravenously and intra‐articularly at a total dose of 2 g pre‐incision and intraoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
2 participants
Very low
Intervention not reported
TXA given orally at a total dose of 2 g pre‐incision and postoperatively · individuals undergoing planned hip or knee replacement surgery Interventions: antifibrinolytics (tranexamic acid, aprotinin or…
1 finding from 1 review
no estimate extracted
2 participants
Low